Damora Therapeutics, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Damora Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $21.71, 36.4% below its 52-week high and below its 200-day average, which is falling.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. More about the company

$21.71

+0.84% today

$1.3B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is DMRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S1 19w

S4 40w

S2 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 2w → S4 12w → S1 2w → S4 2w → S1 19w → S4 1w → S3 3w → S4 13w → S1 2w → S4 40w → S1 10w → S4 4w → S1 1w → S2 25w → S3 1w → S2 3w → S3 11w → S2 10w → S3 3w → S4 1w current

Total tracked: 165 weeks across 21 stage runs.

DMRA among Biotechnology30th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…30	DMRADamora Therapeutics, Inc.	Stage 4 · wk 2	97	+6.2%

vs 52W High

-36.4%

$4.95 lo$34.14 hi

36.4% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-15.4%

200 DMA: $25.67 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.75x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+6.2%

-24.7%

-14.6%

YTD

-0.5%

+154.5%

Scan Membership

Breakout Watch

Latest: 2023-05-30

3 appearances in last 60 days. First seen: 2022-10-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.75x

2026-10-21S4

Wk 1 · Vol 0.98x

2026-10-20S4

Wk 1 · Vol 0.44x

2026-10-19S4

Wk 1 · Vol 0.53x

2026-10-16S4

Wk 1 · Vol 1.53x

2026-10-15S43→4

Wk 1 · Vol 0.65x

2026-10-14S3

Wk 3 · Vol 0.50x

2026-10-13S3

Wk 3 · Vol 0.51x

2026-10-12S3

Wk 3 · Vol 0.48x

2026-10-09S3

Wk 3 · Vol 0.66x

2026-10-08S3

Wk 2 · Vol 0.61x

2026-10-07S3

Wk 2 · Vol 0.88x

Moving averages & range

50 DMA

$24.69

200 DMA

$25.67

52W High

$34.14

52W Low

$4.95

5D Low

$18.44

Resistance levels (recent highs)

20d High

$21.71

60d High

$32.44

120d High

$32.99

250d High

$34.14

Next resistance

+49.4%

to 60d High

ROE

-99.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.5

Damora Therapeutics: quick answers

What stage is Damora Therapeutics in?

As of Oct 22, 2026, Damora Therapeutics (DMRA) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Damora Therapeutics in an uptrend?

No. Damora Therapeutics is in a Stage 4 downtrend. It trades 15.4% below its 200-day average, which is falling.

How far is Damora Therapeutics from its 52-week high?

Damora Therapeutics closed at $21.71 on Oct 22, 2026, 36.4% below its 52-week high of $34.14. Its 52-week low is $4.95.

How has Damora Therapeutics performed over the past year?

As of Oct 22, 2026, Damora Therapeutics is up 154.5% over the past year and down 0.5% so far in 2026.

Which sector and industry is Damora Therapeutics in?

Damora Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.